Beyond Air, Inc. (XAIR) News
Filter XAIR News Items
XAIR News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
XAIR News Highlights
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
Latest XAIR News From Around the Web
Below are the latest news stories about BEYOND AIR INC that investors may wish to consider to help them evaluate XAIR as an investment opportunity.
Insider Stock Buying Reaches US$1.60m On Beyond AirOver the last year, a good number of insiders have significantly increased their holdings in Beyond Air, Inc... |
Beyond Air to Participate in the Lytham Partners 2025 Investor Healthcare Summit on January 13, 2025GARDEN CITY, N.Y., Jan. 06, 2025 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial stage medical device and biopharmaceutical company focused on harnessing the power of nitric oxide (NO) to improve the lives of patients, today announced that Steve Lisi, Chairman and Chief Executive Officer of Beyond Air, will participate in one-on-one meetings and a presentation at the Lytham Partners 2025 Investor Healthcare Summit, taking place virtually on Monda |
Beyond Cancer Announces Approval by the Israeli Ministry of Health to Conduct a Phase 1b Clinical Trial Utilizing Low Volume Ultra-High Concentration Nitric Oxide (LV UNO) in Combination with Anti-PD-1 TherapyThe Phase 1b study will evaluate LV UNO in unresectable cutaneous or subcutaneous histologically confirmed primary or metastatic solid tumor cancer patients that have progressed or have prolonged stable disease on single agent PD-1 inhibitorsThe primary objective of the Phase 1b study is to assess preliminary efficacy by objective response rate (ORR) and duration of response (DOR) per RECIST version 1.1 and secondarily immune-related response via iRECISTThe study will recruit patients from four |
Beyond Air Receives CE Mark in Europe for the LungFit® PH SystemIndication covers newborn infants with hypoxic respiratory failure and peri- and post-operative pulmonary hypertension to improve right ventricular function in conjunction with heart surgery A $1 million milestone payment is triggered from Asia-Pacific partner, Getz Healthcare GARDEN CITY, N.Y., Dec. 02, 2024 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial stage medical device and biopharmaceutical company focused on harnessing the power of nitri |
NeuroNOS Appoints Nobel Laureate, Roger D. Kornberg, to Scientific Advisory BoardProfessor Kornberg will assist in accelerating the development of treatments for Autism Spectrum Disorder and potentially other neurological disordersDUBLIN and GARDEN CITY, N.Y., Nov. 26, 2024 (GLOBE NEWSWIRE) -- NeuroNOS, a pioneering biopharmaceutical company focused on developing transformative treatments for Autism Spectrum Disorder (ASD) and other complex neurological conditions, and a subsidiary of Beyond Air (NASDAQ: XAIR), is proud to announce the appointment of Professor Roger D. Kornb |
Beyond Air to Participate in the Piper Sandler 36th Annual Healthcare ConferenceGARDEN CITY, N.Y., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial stage medical device and biopharmaceutical company focused on harnessing the power of Nitric Oxide (NO) to improve the lives of patients, today announced that Steve Lisi, Chairman and Chief Executive Officer of Beyond Air, will participate in one-on-one meetings and a fireside chat at the Piper Sandler 36th Annual Healthcare Conference being held December 3-5, 2024 i |
Beyond Air® Reports Fiscal Second Quarter 2025 Financial Results and Provides Corporate UpdateRevenues increased 17% compared to the previous quarter ended June 30, 2024 Strengthened balance sheet is expected to provide sufficient cash runway through June 2026 Completed a $20.6 million private placement offering with multiple healthcare-focused institutional funds and Company insiders Retired $17.5 million in debt from Avenue Capital and entered into a $11.5 million loan agreement with an insider-led investor group Conference call scheduled for 4:30 p.m. ET today, November 11th GARDEN CI |
Beyond Cancer Presents Promising Preclinical Data on Low Volume Ultra-High Concentration Nitric Oxide (LV UNO) Therapy at the 2024 Society for Immunotherapy of Cancer (SITC) Annual Meeting- LV UNO in combination with anti-rPD-L1 resulted in prolonged survival and doubled the tumor growth inhibition rate in MAT B III tumor bearing rats compared to anti-rPD-L1 alone - LV UNO compares favorably to HV UNO administration in reducing tumor volumes in combination with anti-mPD-1 in CT26 BALB/c mice - Increased nitro-tyrosine staining in LV UNO treated tumors indicates an improved distribution of UNO in the tumor leading to potentially improved outcomes and an enhanced safety profile HAM |
Beyond Air® Schedules Second Fiscal Quarter 2025 Financial Results Conference Call and WebcastGARDEN CITY, N.Y., Oct. 29, 2024 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial stage medical device and biopharmaceutical company focused on harnessing the power of endogenous and exogenous nitric oxide (NO) to improve the lives of patients, today announced that it plans to report the financial results for the second quarter of its fiscal year 2025 ended September 30, 2024 on Monday, November 11, 2024 after the market closes. Conference Call & |
Beyond Cancer to Present Preclinical Data of Ultra-High Concentration Nitric Oxide (UNO) Low Volume Therapy at the 2024 Society for Immunotherapy of Cancer (SITC) Annual MeetingSubmitted abstracts selected for the annual meeting are scheduled to be released to SITC registrants on Tuesday, November 5th at 9:00 AM U.S. ET Presentations of Beyond Cancer’s two full posters will take place on November 8th and 9th at the SITC Annual Meeting; ePublications of the posters will be available November 7th Therapeutic efficacy of Low Volume (<1L) UNO demonstrated in both mice and rat tumor models HAMILTON, Bermuda, Oct. 07, 2024 (GLOBE NEWSWIRE) -- Beyond Cancer, Ltd., a clinical |